Asset profile
Olanzapine/samidorphan (Qilu)
Small molecule
Evidence outlook · registrational
Schizophrenia: registrational readout pending
Its supporting mid-stage evidence has not yet been graded on this platform. The registry's posted readout date (2026-04) has passed without a status update. Check News for topline announcements.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
67 competitors in this universe: 26 direct rivals (same mechanism and indication), 0 same-class, 41 same-indication; 37 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Olanzapine / Samidorphan (Qilu): this drug | Phase 3 | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist), Dopamine D2 and serotonin 5-HT2A/5-HT2C receptors (antagonist); mu-opioid receptor (antagonist) | ||
| Asenapine | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | ||
| Clozapine | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | ||
| Fazaclo | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | ||
| Iloperidone (PD Psychosis Use) (Fanapt) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | ||
| Loxapine (Adasuve) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | ||
| Lurasidone | Approved | Small molecule | Dopamine D2/D3 receptor + 5-HT7 receptor, Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | ||
| Milsaperidone (VHX-896) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | ||
| Olanzapine (Zyprexa Relprevv) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | ||
| Olanzapine (Zyprexa) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | ||
| Paliperidone (Invega) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | ||
| Paliperidone Palmitate (Erzofri) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | ||
| Paliperidone Palmitate (Invega Hafyera) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | ||
| Paliperidone Palmitate (Invega Sustenna) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | ||
| Paliperidone Palmitate (Invega Trinza) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | ||
| Perseris | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) |
…and 52 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
18 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2027 (1)
April 2027 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.